Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Keros Therapeutics Inc (KROS)

Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stocks Settle Lower as Bond Yields Climb

The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.68%. Stock indexes...

AMAT : 163.59 (+1.33%)
CVS : 44.36 (+1.32%)
AVGO : 220.79 (+1.13%)
$IUXX : 21,289.15 (+0.85%)
UNH : 500.13 (+2.22%)
ZNH25 : 108-310s (+0.33%)
QCOM : 152.89 (+1.66%)
JAZZ : 122.97 (+0.10%)
KDP : 32.37 (-0.09%)
LRCX : 71.79 (+0.81%)
WBD : 10.69 (+1.91%)
$DOWI : 42,840.26 (+1.18%)
Keros Therapeutics Announces Voluntary Halt of Dosing in TROPOS Trial Due to Safety Review Findings

Keros Therapeutics halts certain dosing in TROPOS trial due to safety concerns while continuing to collect safety and efficacy data.Quiver AI SummaryKeros Therapeutics, Inc. has announced the voluntary...

KROS : 17.03 (+0.65%)
Stocks Pressured by Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.41%. Stock indexes today are posting...

AMAT : 163.59 (+1.33%)
AVGO : 220.79 (+1.13%)
$IUXX : 21,289.15 (+0.85%)
ZNH25 : 108-310s (+0.33%)
QCOM : 152.89 (+1.66%)
JAZZ : 122.97 (+0.10%)
EFX : 258.43 (+1.88%)
KDP : 32.37 (-0.09%)
LRCX : 71.79 (+0.81%)
WBD : 10.69 (+1.91%)
$DOWI : 42,840.26 (+1.18%)
CACI : 402.72 (+0.70%)
Keros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A Rebound

Optimistic retail users highlighted Keros’ broader pipeline, including its potential in obesity treatments and other promising partnerships.

KROS : 17.03 (+0.65%)
Stocks Weaken on Stagflation Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.58%. Stock indexes today are mildly...

AMAT : 163.59 (+1.33%)
AVGO : 220.79 (+1.13%)
$IUXX : 21,289.15 (+0.85%)
ZNH25 : 108-310s (+0.33%)
QCOM : 152.89 (+1.66%)
JAZZ : 122.97 (+0.10%)
EFX : 258.43 (+1.88%)
KDP : 32.37 (-0.09%)
LRCX : 71.79 (+0.81%)
WBD : 10.69 (+1.91%)
$DOWI : 42,840.26 (+1.18%)
CACI : 402.72 (+0.70%)
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

KROS : 17.03 (+0.65%)
Keros Therapeutics Reports Positive Phase 2 Data for Elritercept in Lower-Risk Myelodysplastic Syndromes and Myelofibrosis at ASH 2024

Elritercept shows promise for treating lower-risk myelodysplastic syndromes and myelofibrosis, demonstrating durable transfusion independence and improving patient-reported outcomes.Quiver AI SummaryKeros...

KROS : 17.03 (+0.65%)
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

KROS : 17.03 (+0.65%)
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

KROS : 17.03 (+0.65%)
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

KROS : 17.03 (+0.65%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar